Michigan Medicine researchers have been developing an “artificial placenta,” an extracorporeal system that replicates the fetal environment and could someday improve care for extremely premature infants. Thinning of the blood with heparin would create a prohibitively high risk of bleeding and remained a critical milestone to human use of the artificial placenta. George Mychaliska, M.D., a professor of surgery at the University of Michigan Medical School discusses the clinical translations of the artificial placenta.
